Saturday, June 29, 2013

Mitchell 2010 Chevrolet Silverado 2500HD Used Truck near Sioux Falls, SD Brookings, SD Vern Eide Ford Lincoln for $

  • Blue Granite Metallic
  • Light Titanium/Ebony Accents w/Premium Cloth Seat
  • F93057A
  • 6.0L V8
  • 1GC4KXBGXAF144068
  • Automatic 6-Speed
  • 24,983 mi.
  • 4WD Truck (4 Door Crew Cab)

0|2857

CARFAX

?

  • Convenience

    • Air conditioning
    • Cruise control
    • Overhead console - Mini
    • Power steering
    • Tilt steering wheel
    • Clock - In-radio display
    • Compass
    • External temperature display
    • Tachometer
    • Remote power door locks
    • Power heated mirrors
    • Power windows with 1 one-touch
    • Remote Start
  • Exterior

    • Chrome grill
    • Engine hour meter
    • Pickup Bed Type - Regular
    • Intermittent window wipers
    • Privacy/tinted glass
    • Tow Package
  • Interior

  • Optional Equipment

    • Alloy Wheels
    • Dual Climate Controls
    • Onstar
    • Powered Seat
    • Running Boards
    • Tonneau Cover
    • XM Radio
  • Safety

    • 4-wheel ABS brakes
    • Passenger Airbag - Cancellable
    • Daytime running lights
    • Dusk sensing headlights
  • Technical

    • 4WD Type - Part-time
    • Bed Length - 97.8 "
    • 4 Doors
    • Four-wheel drive
    • Automatic Transmission
  • Not all issues are reported to CARFAX. The number of owners is estimated. See the full CARFAX Report for additional information and glossary of terms.

?

Contact Us at (800) 778-0215

EPA mileage estimates are for newly manufactured vehicles only. Your actual mileage will vary depending on how you drive and maintain your vehicle.

Before purchasing this vehicle, it is your responsibility to address any and all differences between information on this website and the actual vehicle specifications and/or any warranties offered prior to the sale of this vehicle. Vehicle data on this website is compiled from publicly available sources believed by the publisher to be reliable. Vehicle data is subject to change without notice. The publisher assumes no responsibility for errors and/or omissions in this data the compilation of this data and makes no representations express or implied to any actual or prospective purchaser of the vehicle as to the condition of the vehicle, vehicle specifications, ownership, vehicle history, equipment/accessories, price or warranties.

Source: http://verneideford.com/2010-Chevrolet-Silverado-2500HD-Mitchell/vd/15499733

jessica chastain jessica chastain oscars jane fonda

Monday, June 17, 2013

Researchers demonstrate use of stem cells to analyze causes, treatment of diabetes

June 17, 2013 ? A team from the New York Stem Cell Foundation (NYSCF) Research Institute and the Naomi Berrie Diabetes Center of Columbia University has generated patient-specific beta cells, or insulin-producing cells, that accurately reflect the features of maturity-onset diabetes of the young (MODY).

The researchers used skin cells of MODY patients to produce induced pluripotent stem (iPS) cells, from which they then made beta cells. Transplanted into a mouse, the stem cell-derived beta cells secreted insulin in a manner similar to that of the beta cells of MODY patients. Repair of the gene mutation restored insulin secretion to levels seen in cells obtained from healthy subjects. The findings were reported today in the Journal of Clinical Investigation.

Previous studies have demonstrated the ability of human embryonic stem cells and iPS cells to become beta cells that secrete insulin in response to glucose or other molecules. But the question remained as to whether stem cell-derived beta cells could accurately model genetic forms of diabetes and be used to develop and test potential therapies.

"We focused on MODY, a form of diabetes that affects approximately one in 10,000 people. While patients and other models have yielded important clinical insights into this disease, we were particularly interested in its molecular aspects -- how specific genes can affect responses to glucose by the beta cell," said co-senior author Dieter Egli, PhD, Senior Research Fellow at NYSCF, who was named a NYSCF-Robertson Stem Cell Investigator in 2012.

MODY is a genetically inherited form of diabetes. The most common form of MODY, type 2, results in a loss-of-function mutation in one copy of the gene that codes for the sugar-processing enzyme glucokinase (GCK). With type 2 MODY, higher glucose levels are required for GCK to metabolize glucose, leading to chronic, mildly elevated blood sugar levels and increased risk of vascular complications.

MODY patients are frequently misdiagnosed with type 1 or 2 diabetes. Proper diagnosis can not only change the patient's course of treatment but affect family members, who were previously unaware that they, too, might have this genetic disorder.

NYSCF scientists took skin cells from two Berrie Center type 2 MODY patients and "reprogrammed" -- or reverted -- them to an embryonic-like state to become iPS cells. To examine the effect of the GCK genetic mutation, they also created two genetically manipulated iPS cell lines for comparison: one fully functional (two correct copies of the GCK gene) and one with complete loss of function (two faulty copies of the GCK gene). They then generated beta cell precursors from the fully functional and loss-of-function iPS cell lines and transplanted the cells for further maturation into immune-compromised mice.

"Our ability to create insulin-producing cells from skin cells, and then to manipulate the GCK gene in these cells using recently developed molecular methods, made it possible to definitively test several critical aspects of the utility of stem cells for the study of human disease," said Haiqing Hua, PhD, lead author on the paper, a postdoctoral fellow in the Division of Molecular Genetics, Department of Pediatrics and Naomi Berrie Diabetes Center at Columbia University and the New York Stem Cell Foundation Research Institute.

When given a glucose tolerance test three months later, mice with MODY beta cells had decreased sensitivity to glucose but a normal response to other molecules that stimulate insulin secretion. This is the hallmark of MODY. Mice with two faulty copies of the GCK gene secreted no additional insulin in response to glucose. When the researchers repaired the GCK mutation using molecular techniques, cells with two restored copies of GCK responded normally to the glucose stress test. Unlike other reported techniques, the researchers' approach efficiently repaired the GCK mutation without introducing any potentially harmful additional DNA.

"Generation of patient-derived beta cells with gene correction could ultimately prove to be a useful cell-replacement therapy by restoring patients' ability to regulate their own glucose. This result is truly exciting," said Susan L. Solomon, Chief Executive Officer of The New York Stem Cell Foundation.

The researchers also used an electron microscope to assess beta cells for insulin content by counting granules -- packages that store insulin for release. Even though all beta cell types had a similar number of granules, complete loss of function of the GCK gene was associated with decreased beta-cell production.

"These studies provide a critical proof-of-principle that genetic characteristics of patient-specific insulin-producing cells can be recapitulated through use of stem cell techniques and advanced molecular biological manipulations. This opens up strategies for the development of new approaches to the understanding, treatment, and, ultimately, prevention of more common types of diabetes," said co-senior author Rudolph Leibel, MD, Christopher Murphy Memorial Professor of Diabetes Research, Columbia University Medical Center, and Director, Division of Molecular Genetics, and Co-Director of the Naomi Berrie Diabetes Center.

The other authors are: Linshan Shang and Hector Martinez of the New York Stem Cell Foundation Research Institute; and Matthew Freeby, Mary Pat Gallagher, Thomas Ludwig, Liyong Deng, Ellen Greenberg, Charles LeDuc, Wendy K. Chung, and Robin Goland of the Division of Molecular Genetics, Department of Pediatrics, and Naomi Berrie Diabetes Center at Columbia University.

Funding for this study was provided by: The New York Stem Cell Foundation; the Russell Berrie Foundation; the Leona M. and Harry B. Helmsley Charitable Trust; the Hunter Eastman Scholar Award in Translational Diabetes Research; the James and Irene Hunter Charitable Fund; an ADA-Mentored Fellowship to H. Hua; and NIH Grants RO1 DK52431 and P30DK063608.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/~3/FXGpi6up-oM/130617173129.htm

jenelle evans jenelle evans glenn beck AJ Clemente Thor 2 Trailer

Wednesday, June 12, 2013

Feds: All girls to have morning-after pill access

FILE - This undated file photo provided by Barr Pharmaceuticals Inc., shows a package of Plan B One-Step, an emergency contraceptive. The federal government on Monday, June 10, 2013 told a judge it will reverse course and take steps to comply with his order to allow girls of any age to buy emergency contraception without prescriptions. (AP Photo/Barr Pharmaceuticals Inc., File)

FILE - This undated file photo provided by Barr Pharmaceuticals Inc., shows a package of Plan B One-Step, an emergency contraceptive. The federal government on Monday, June 10, 2013 told a judge it will reverse course and take steps to comply with his order to allow girls of any age to buy emergency contraception without prescriptions. (AP Photo/Barr Pharmaceuticals Inc., File)

(AP) ? The federal government on Monday told a judge it will reverse course and take steps to comply with his order to allow girls of any age to buy emergency contraception without prescriptions.

The decision ends a years-long fight between President Barack Obama's administration, which had argued that age limits for the morning-after pill are common sense, and women's rights groups, which insisted the drug should be made as freely available as aspirin.

The Department of Justice, in the latest development in the complex back-and-forth over access to the drug, notified U.S. District Judge Edward Korman it will submit a plan for compliance. If he approves it, the department will drop its appeal of his April ruling.

According to the department's letter to the judge, the Food and Drug Administration has told the maker of the pills to submit a new drug application with proposed labeling that would permit it to be sold "without a prescription and without age or point-of-sale prescriptions." The FDA said that once it receives the application it "intends to approve it promptly."

Last week, an appeals court dealt the government a setback by saying it would immediately permit unrestricted sales of the two-pill version of the emergency contraception until the appeal was decided. That order was met with praise from advocates for girls' and women's rights and with scorn from social conservatives and other opponents, who argue the drug's availability takes away the rights of parents of girls who could get it without their permission.

Advocates for girls' and women's rights said Monday the federal government's decision to comply with the judge's ruling could be a move forward for "reproductive justice" if the FDA acts quickly and puts emergency contraception over the counter without restriction.

Annie Tummino, lead plaintiff in a lawsuit over unrestricted access to the morning-after pill and coordinator of the National Women's Liberation, said women and girls should have "the absolute right to control our bodies without having to ask a doctor or a pharmacist for permission."

"It's about time that the administration stopped opposing women having access to safe and effective birth control," she said in an emailed statement.

Planned Parenthood Federation of America president Cecile Richards, in a statement, called the government's decision to drop the appeal "a huge breakthrough for access to birth control and a historic moment for women's health and equity."

But opponents of easy access to the morning-after pill, such as the anti-abortion Family Research Council, criticized the government for not sticking with its decision to appeal.

"We're very concerned and disappointed at the same time because what we see here is the government caving to political pressure instead of putting first the health and safety of girls (and) parental rights," said Anna Higgins, director of the council's Center for Human Dignity.

The government had appealed the judge's underlying April 5 ruling, which ordered emergency contraceptives based on the hormone levonorgestrel be made available without a prescription, over the counter and without point-of-sale or age restrictions.

It had asked the judge to suspend the effect of that ruling until the appeals court could decide the case. But the judge declined, saying the government's decision to restrict sales of the morning-after pill was "politically motivated, scientifically unjustified and contrary to agency precedent." He also said there was no basis to deny the request to make the drugs widely available.

The government had argued that "substantial market confusion" could result if the judge's ruling were enforced while appeals were pending, only to be later overturned.

The morning-after pill contains a higher dose of the female hormone progestin than is in regular birth control pills. Taking it within 72 hours of rape, condom failure or just forgetting regular contraception can cut the chances of pregnancy by up to 89 percent, but it works best within the first 24 hours. If a girl or woman already is pregnant, the pill, which prevents ovulation or fertilization of an egg, has no effect.

The FDA was preparing in 2011 to allow over-the-counter sales of the morning-after pill with no limits when Health and Human Services Secretary Kathleen Sebelius overruled her own scientists in an unprecedented move.

The FDA announced in late April that Plan B One-Step, the newer version of emergency contraception, the same drug but combined into one pill instead of two, could be sold without a prescription to those age 15 or older. Its maker, Teva Women's Health, plans to begin those sales soon. Sales had previously been limited to those who were at least 17.

The judge later ridiculed the FDA changes, saying they established "nonsensical rules" that favored sales of the Plan B One-Step morning-after pill and were made "to sugarcoat" the government's appeal.

He also said they placed a disproportionate burden on blacks and the poor by requiring a prescription for less expensive generic versions of the drug bought by those under age 17 and by requiring those age 17 or over to show proof-of-age identification at pharmacies. He cited studies showing that blacks with low incomes are less likely than other people to have government-issued IDs.

The decision marks a sharp reversal for Obama and his administration. His previous decision to appeal set off a storm of criticism from girls' and women's rights groups, who denounced it as politically motivated and a step backward for their health. Abortion rights advocates who had counted Obama as among their supporters angrily questioned why a Democratic president had sided with social conservatives in favor of limiting women's health care choices.

Reluctant to get drawn into a messy second-term spat over social issues, White House officials have argued that the FDA and the Department of Justice were acting independently of the White House in deciding how to proceed. That approach continued Monday, with the White House referring all questions about the decision to Health and Human Services.

Still, Obama has made clear in the past that he feels strongly about the limits, and he said in 2011 he supported Sebelius' decision to impose them despite the advice of her scientists.

"As the father of two daughters, I think it is important for us to make sure that we apply some common sense to various rules when it comes to over-the-counter medicine," Obama said then.

___

Associated Press writer Josh Lederman contributed to this report from Washington.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/386c25518f464186bf7a2ac026580ce7/Article_2013-06-10-Morning-After%20Pill/id-1cd61510e2314321943f549c1ab8997b

Jodi Arias trial cinco de mayo Mike Jeffries Abercrombie Charles Ramsey Interview

Monday, June 10, 2013

AP sources: US close to OK on arming Syrian rebels

FILE -- In this June 5, 2013 file photo released, by the Syrian official news agency SANA, a damaged street is seen in Qusair, Syria. Syria's civil war has morphed into a proxy fight in which Shiite Iran has strongly backed Assad, while Sunni Arab nations have backed rebels. Many Sunni hard-liners around the Mideast have taken Hezbollah's intervention in Syria almost as a declaration of war by Shiites against Sunnis. (AP Photo/SANA, File)

FILE -- In this June 5, 2013 file photo released, by the Syrian official news agency SANA, a damaged street is seen in Qusair, Syria. Syria's civil war has morphed into a proxy fight in which Shiite Iran has strongly backed Assad, while Sunni Arab nations have backed rebels. Many Sunni hard-liners around the Mideast have taken Hezbollah's intervention in Syria almost as a declaration of war by Shiites against Sunnis. (AP Photo/SANA, File)

FILE -- In this Friday, Dec. 28, 2012 file photo, Shiekh Youssef al-Qaradawi, gives the sermon during the Friday prayer at Al-Azhar mosque in Cairo, Egypt. Syria's civil war has morphed into a proxy fight in which Shiite Iran has strongly backed Assad, while Sunni Arab nations have backed rebels. Many Sunni hard-liners around the Mideast have taken Hezbollah's intervention in Syria almost as a declaration of war by Shiites against Sunnis. (AP Photo/Khalil Hamra, File)

(AP) ? Moved by the Assad regime's rapid advance, the Obama administration could decide this week to approve lethal aid for the beleaguered Syrian rebels and will weigh the merits of a less likely move to send in U.S. airpower to enforce a no-fly zone over the civil war-wracked nation, officials said Sunday.

White House meetings are planned over the coming days, as Syrian President Bashar Assad's government forces are apparently poised for an attack on the key city of Homs, which could cut off Syria's armed opposition from the south of the country. As many as 5,000 Hezbollah fighters are now in Syria, officials believe, helping the regime press on with its campaign after capturing the town of Qusair near the Lebanese border last week.

Opposition leaders have warned Washington that their rebellion could face devastating and irreversible losses without greater support, and the warnings are prompting the United States to consider drastic action.

Secretary of State John Kerry postponed a planned trip Monday to Israel and three other Mideast countries to participate in White House discussions, said officials who weren't authorized to speak publicly on the matter and demanded anonymity.

While nothing has been concretely decided, U.S. officials said President Barack Obama was leaning closer toward signing off on sending weapons to vetted, moderate rebel units. The U.S. has spoken of possibly arming the opposition in recent months but has been hesitant because it doesn't want al-Qaida-linked and other extremists fighting alongside the anti-Assad militias to end up with the weapons.

Obama already has ruled out any intervention that would require U.S. military boots on the ground. Other options such as deploying American air power to ground the regime's jets, gunships and other aerial assets are now being more seriously debated, the officials said, while cautioning that a no-fly zone or any other action involving U.S. military deployments in Syria were far less likely right now.

The president also has declared chemical weapons use by the Assad regime a "red line" for more forceful U.S. action. American allies including France and Britain have say they've determined with near certitude that Syrian forces have used low levels of sarin in several attacks, but the administration is still studying the evidence. The U.S. officials said responses that will be mulled over in this week's meetings concern the deteriorating situation on the ground in Syria, independent of final confirmation of possible chemical weapons use.

White House spokeswoman Bernadette Meehan said Obama's advisers were considering all options to hasten a transition in Syria.

"The United States will continue to look for ways to strengthen the capabilities of the Syrian opposition," she said.

Any intervention could have wide-reaching ramifications for the United States and the region. It would bring the U.S. closer to a conflict that has killed almost 80,000 people since Assad cracked down on protesters inspired by the Arab Spring in March 2011 and sparked a war that has since been increasingly defined by sectarian clashes between the Sunni-led rebellion and Assad's Alawite-dominated regime.

And it would essentially pit the United States alongside regional allies Saudi Arabia, Turkey and Qatar in a proxy war against Iran, which is providing much of the materiel to the Syrian government's counterinsurgency and, through Hezbollah, more and more of the manpower.

Syria's precarious position in the heart of the Middle East makes the conflict extremely unpredictable. Lebanon, across the western border, suffered its own brutal civil war in the 1970s and the 1980s and is already experiencing increased interethnic tensions. Iraq, to Syria's east, is mired in worsening violence. And Israel to the southwest has seen shots fired across the contested Golan Heights and has been forced to strike what it claimed were advanced weapons convoys heading to Hezbollah, with whom it went to war with in 2006.

Iran could wreak havoc in the region through its support of Shiite militant groups, and U.S. officials fear Iran may seek to retaliate for any stepped-up American involvement by targeting Israel or U.S. interests in the region. It's also unclear what American action would mean for relations with Russia, which has provided Assad with military and diplomatic support even as it claims that it working with the United States to try to organize a Syrian peace conference.

At the same time, it's unclear how Washington could fundamentally change the trajectory of a conflict that has increasingly tilted toward Assad in recent months without providing weapons to the opposition forces or getting involved itself.

The administration has been studying for months how to rebalance Syria's war so that moderate, pro-democracy rebels defeat the regime or make life so difficult for Assad and his supporters that the government decides it must join a peace process that entails a transition away from the Assad family's four-decade dictatorship.

But Assad's military successes appear to have rendered peace efforts largely meaningless in the short term. While Kerry and his Russian counterpart Sergey Lavrov have been trying to rally support for the planned conference in Geneva ? first envisioned for May and since postponed until July at the earliest ? even America's allies in the Syrian opposition leadership have questioned the wisdom of sitting down for talks while they are ceding territory all over the country to Assad's forces.

Beyond weapons support for the rebels, administration officials harbor deep reservations about other options.

They note that a no-fly zone, championed by hawks in Congress such as Sen. John McCain, R-Ariz., would require the U.S. to first neutralize Syrian air defense systems that have been reinforced with Russian technology and are far stronger than those that Libyan dictator Moammar Gadhafi had before the U.S. and its Arab and European allies helped rebels overthrow him in 2011. And unlike with Libya, Washington has no clear international mandate for authorizing any strikes inside Syria, a point the Obama administration has harped on since late 2011 to explain its reticence about more forceful action.

Homs has one of the biggest Alawite communities in Syria and is widely seen as pro-Assad. The rebels control the city center, however, with regime forces besieging them on the outskirts.

Many towns north of Homs also are rebel-controlled, while to the south Hezbollah-backed government forces have been clearing rebels from villages and towns. Fierce fighting there over the past three weeks has killed dozens of rebels, troops and Hezbollah fighters and wounded hundreds.

Seizing control of Homs would clear a path for the regime from Damascus to the Mediterranean coast, and firm up its grip on much of the country.

___

AP White House Correspondent Julie Pace contributed to this report.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/89ae8247abe8493fae24405546e9a1aa/Article_2013-06-09-US-Syria/id-e6d9337eba104b5b84b4360a0804c2fd

St Patrick